Antiparkinson drug adherence and its association with health care utilization and economic outcomes in a medicare Part D population

Value in Health

Volumn 17, Issue 2, 2014, Pages 196-204

  Wei, Yu Jung ^a   Palumbo, Francis B ^a   Simoni Wastila, Linda ^a   Shulman, Lisa M ^b   Stuart, Bruce ^a   Beardsley, Robert ^a   Brown, Clayton H ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF PHARMACY   (United States)

^b UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

antiparkinson drug; expenditures; health care utilization; Medicare; medication adherence

Indexed keywords

AMANTADINE; ANTIPARKINSON AGENT; CATECHOL METHYLTRANSFERASE INHIBITOR; CHOLINERGIC RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR;

AGED; ARTICLE; CLINICAL PRACTICE; FEMALE; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HELP SEEKING BEHAVIOR; HOME HEALTH AGENCY; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICARE; OUTCOME ASSESSMENT; PARKINSON DISEASE; PATIENT COMPLIANCE; PHYSICIAN; PRESCRIPTION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SAMPLING; SKILLED NURSING FACILITY; SURVIVAL; TREATMENT DURATION; VERY ELDERLY;

ANTIPARKINSON DRUG; EXPENDITURES; HEALTH CARE UTILIZATION; MEDICARE; MEDICATION ADHERENCE;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; CROSS-SECTIONAL STUDIES; FEMALE; HEALTH EXPENDITURES; HEALTH SERVICES; HUMANS; LINEAR MODELS; MALE; MEDICARE PART D; MEDICATION ADHERENCE; MIDDLE AGED; PARKINSON DISEASE; PATIENT ACCEPTANCE OF HEALTH CARE; RETROSPECTIVE STUDIES; TIME FACTORS; UNITED STATES;

EID: 84896382847     PISSN: 10983015     EISSN: 15244733     Source Type: Journal    
DOI: 10.1016/j.jval.2013.12.003     Document Type: Article

References (58)

1. R.L. Nussbaum, and C.E. Ellis Alzheimer's disease and Parkinson's disease N Engl J Med 348 2003 1356 1364 (Pubitemid 36384104)
2. R. Mayeux, J. Denaro, and N. Hemenegildo et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender Arch Neurol 49 1992 492 497
3. A. Wright Willis, B.A. Evanoff, and M. Lian et al. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries Neuroepidemiology 34 2010 143 151
4. J.A. O'Brien, A. Ward, and S.L. Michels et al. Economic burden associated with Parkinson disease. Drug Benefit Trends 21 2009 179 190
5. J.G. Nutt, and G.F. Wooten Clinical practice. Diagnosis and initial management of Parkinson's disease N Engl J Med 353 2005 1021 1027 (Pubitemid 41262336)
6. E.R. Dorsey, R. Constantinescu, and J.P. Thompson et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030 Neurology 68 2007 384 386 (Pubitemid 46184217)
7. Treatment of central nervous system degenerative disorders: Parkinson's disease (PD). In: Brunton LL, ed., Goodman & Gilman's Pharmacology. New York, NY: McGraw-Hill, 2007
8. M.A. Koda-Kimble, L.Y. Young, and B.K. Alldredge et al. Applied Therapeutics - The Clinical Use of Drugs 9th ed. 2008 Lippincott Williams & Wilkins San Francisco, CA
9. O. Rascol, C. Goetz, and W. Koller et al. Treatment interventions for Parkinson's disease: an evidence based assessment Lancet 359 2002 1589-8
10. D. Grosset Therapy adherence issues in Parkinson's disease J Neurol Sci 289 2010 115 118
11. M.L. Tarrants, M.F. Denarie, and J. Castelli-Haley et al. Drug therapies for Parkinson's disease: a database analysis of patient compliance and persistence Am J Geriatr Pharmacother 8 2010 374 383
12. N.A. Leopold, M. Polansky, and M.R. Hurka Drug adherence in Parkinson's disease Mov Disord 19 2004 513 517
13. J.L. Bainbridge, and J.M. Ruscin Challenges of treatment adherence in older patients with Parkinson's disease Drugs Aging 26 2009 145 155
14. K.A. Grosset, I. Bone, and D.G. Grosset Suboptimal medication adherence in Parkinson's disease Mov Disord 20 2005 1502 1507 (Pubitemid 43072661)
15. J.K. Dobson, R.L. Rodnitzky, and E. Uc Compliance among clinical trial participants in Parkinson's disease: can it be predicted? Mov Disord 19 Suppl. 9 2004 S245 S282
16. K.A. Grosset, J.L. Reid, and D.G. Grosset Medicine-taking behavior: implications of suboptimal compliance in Parkinson's disease Mov Disord 20 2005 1397 1404 (Pubitemid 43072646)
17. A.S. Kulkarni, R. Balkrishnan, and R.T. Anderson et al. Medication adherence and associated outcomes in Medicare health maintenance organization-enrolled older adults with Parkinson's disease Mov Disord 23 2008 359 365
18. K.L. Davis, H.M. Edin, and J.K. Allen Prevalence and cost of medication nonadherence in Parkinson's disease: evidence from administrative claims data Mov Disord 25 2010 474 480
19. W.H. Shrank, A.R. Patrick, and M.A. Brookhart Healthy user and related biases in observational studies of preventive interventions: a primer for physicians J Gen Intern Med 26 2011 546 550
20. M.A. Brookhart, A.R. Patrick, and C. Dormuth et al. Adherence to lipid-lowering therapy and the use of preventive health services: an investigation of the healthy user effect Am J Epidemiol 166 2007 348 354 (Pubitemid 47216808)
21. A.B. Platt, S.T. Kuna, and S.H. Field et al. Adherence to sleep apnea therapy and use of lipid-lowering drugs: a study of the healthy-user effect Chest 137 2009 102 108
22. R.W. Thomsen The lesser known effects of statins: benefits on infectious outcomes may be explained by "healthy user" effect BMJ 333 2006 980 981
23. CMS Chronic Conditions Data Warehouse. CCW user manual. Available from: http://www.ccwdata.org/datadoc.php. [Accessed January 23, 2010].
24. A.M. Peterson, D.P. Nau, and J.A. Cramer et al. A checklist for medication compliance and persistence studies using retrospective databases Value Health 10 2007 3 12 (Pubitemid 46161090)
25. S. Karve, M.A. Cleves, and M. Helm et al. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients Med Care 46 2008 1125 1133
26. U.S. Food and Drug Administration. Safety information - Neupro (rotigotine transdermal system). Available from: http://www.fda.gov/Safety/ MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm094861.htm. [Accessed January 30, 2010].
27. U.S. Food and Drug Administration. Pergolide (marketed as Permax) information. Available from: http://www.fda.gov/cder/drug/infopage/pergolide/ default.htm. [Accessed January 30, 2008].
28. J.A. Cramer, A. Roy, and A. Burrell et al. Medication compliance and persistence: terminology and definitions Value Health 11 2008 44 47 (Pubitemid 351160875)
29. S.E. Andrade, K.H. Kahler, and F. Frech et al. Methods for evaluation of medication adherence and persistence using automated databases Pharmacoepidemiol Drug Saf 15 2006 565 574 discussion 575-67 (Pubitemid 44336271)
30. N.K. Choudhry, W.H. Shrank, and R.L. Levin et al. Measuring concurrent adherence to multiple related medications Am J Manag Care 15 2009 457 464
31. Office of Inspector General. Medicare Part D Payments for Beneficiaries in Part A Skilled Nursing Facility Stays in 2006. Washington, DC: DHHS, 2009.
32. E. Saka, and B. Elibol Enhanced cued recall and clock drawing test performances differ in Parkinson's and Alzheimer's disease-related cognitive dysfunction Parkinsonism Relat Disord 15 2009 688 691
33. C.H. Williams-Gray, T. Foltynie, and S.J. Lewis et al. Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options CNS Drugs 20 2006 477 505 (Pubitemid 43830737)
34. G.C. Pope, J. Kautter, and R.P. Ellis et al. Risk adjustment of Medicare capitation payments using the CMS-HCC model Health Care Financ Rev 25 2004 119 141 (Pubitemid 39201560)
35. E.M. Brown, and V. Goel Factors related to emergency department use: results from the Ontario Health Survey 1990 Ann Emerg Med 24 1994 1083 1091 (Pubitemid 24368145)
36. K. Jordan, B.N. Ong, and P. Croft Previous consultation and self reported health status as predictors of future demand for primary care J Epidemiol Community Health 57 2003 109 113 (Pubitemid 36160618)
37. A. Walter-Ginzburg, A. Chetrit, and C. Medina et al. Physician visits, emergency room utilization, and overnight hospitalization in the old-old in Israel: the cross-sectional and longitudinal aging study (CALAS) J Am Geriatr Soc 49 2001 549 556 (Pubitemid 32525024)
38. Centers for Medicare & Medicaid Services. Medicare claims processing manual. Chapter 18 - preventive and screening services. Available from: https://www.cms.gov/manuals/downloads/clm104c18.pdf. [Accessed January 30, 2010].
39. U.S. Preventive Services Task Force Guide to Clinical Preventive Services, 2008: Recommendations of the U.S. Preventive Services Task Force. Publication No. 08-05122 2008 Agency for Healthcare Research and Quality Rockville, MD
40. National Cancer Institute. Prostate-specific antigen (PSA) test. Available from: http://www.cancer.gov/cancertopics/factsheet/detection/PSA. [Accessed August 22, 2013].
41. D.K. Blough, and S.D. Ramsey Using generalized linear models to assess medical care costs Health Serv Outcomes Res Methodol 1 2000 185 202 (Pubitemid 32798848)
42. J. Barber, and S. Thompson Multiple regression of cost data: use of generalised linear models J Health Serv Res Policy 9 2004 197 204 (Pubitemid 39424759)
43. V. Fung, R.J. Brand, and J.P. Newhouse et al. Using Medicare data for comparative effectiveness research: opportunities and challenges Am J Manag Care 17 2011 488 496
44. J.J. Heckman Sample selection bias as a specification error Econometrica 47 1979 153 161
45. Centers for Medicare & Medicaid Services. Medicare Advantage Landscape Source files. Available from: http://www.cms.gov/Medicare/ Prescription-Drug-Coverage/PrescriptionDrugCovGenIn/index.html?redirect=/ PrescriptionDrugCovGenIn/. [Accessed June 30, 2008].
46. Agency for Healthcare Research and Quality. Medical Expenditure Panel Survey. Available from: http://www.ahrq.gov/research/data/meps/index.html. [Accessed January 30, 2008].
47. N.R. Szumski, and E.M. Cheng Optimizing algorithms to identify Parkinson's disease cases within an administrative database Mov Disord 24 2009 51 56
48. K. Swarztrauber, J. Anau, and D. Peters Identifying and distinguishing cases of parkinsonism and Parkinson's disease using ICD-9 CM codes and pharmacy data Mov Disord 20 2005 964 970 (Pubitemid 41419511)
49. Research Triangle Park. Medicare Part D program evaluation: analysis of the impact of Medicare Part D on the FFS program and issues related to medication adherence for six chronic conditions-2007. Available from: http://www.cms.hhs.gov/Research-Statistics-Data-and-Systems/Statistics-Trends- and-Reports/Reports/Downloads/Ingber-MedicareDEvalComplete-2007.pdf. [Accessed April 16, 2012].
50. J.R. Curtis, J. Xi, and A.O. Westfall et al. Improving the prediction of medication compliance: the example of bisphosphonates for osteoporosis Med Care 47 2009 334 341
51. W. Katon, C.R. Cantrell, and M.C. Sokol et al. Impact of antidepressant drug adherence on comorbid medication use and resource utilization Arch Intern Med 165 2005 2497 2503 (Pubitemid 41720012)
52. The Henry J. Kaiser Family Foundation. Examining sources of supplemental insurance and prescription drug coverage among Medicare beneficiaries: findings from the Medicare Current Beneficiary Survey, 2007. Available from: http://kaiserfamilyfoundation.files.wordpress.com/2013/01/7801-02.pdf. [Accessed August 30, 2013].
53. D. Aarsland, J.P. Larsen, and E. Tandberg et al. Predictors of nursing home placement in Parkinson's disease: a population-based, prospective study J Am Geriatr Soc 48 2000 938 942 (Pubitemid 30637303)
54. E. Stefanova, A. Potrebic, and L. Ziropadja et al. Depression predicts the pattern of cognitive impairment in early Parkinson's disease J Neurol Sci 248 2006 131 137 (Pubitemid 44649253)
55. H. Reichmann, C. Schneider, and M. Lohle Non-motor features of Parkinson's disease: depression and dementia Parkinsonism Relat Disord 15 Suppl. 3 2009 S87 S92
56. H. Reichmann, P. Odin, and H.M. Brecht et al. Changing dopamine agonist treatment in Parkinson's disease: experiences with switching to pramipexole J Neural Transm Suppl 71 2006 17 25 (Pubitemid 351412102)
57. D.J. Daley, P.K. Myint, and R.J. Gray et al. Systematic review on factors associated with medication non-adherence in Parkinson's disease Parkinsonism Relat Disord 18 2012 1053 1061
58. K.J. Burchiel, V.C. Anderson, and J. Favre et al. Comparison of pallidal and subthalamic nucleus deep brain stimulation for advanced Parkinson's disease: results of a randomized, blinded pilot study Neurosurgery 45 1999 1375 1382 discussion 1382-74